加载中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$0.3378
−US$0.0922 · -21.44%
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
前收盘价
US$0.3378
−US$0.0922 · -21.44%
盘中时间采用ET。市场数据可能有所延迟。
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
日内区间
当前US$0.3378
52周区间
当前US$0.3378
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
54
合理估值
情绪
58
多空交织
风险
71
高风险
动量
17
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
日内区间
当前US$0.3378
52周区间
当前US$0.3378
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 3630.59万 USD | 3487.43万 USD | 2409.28万 USD | 434.56万 USD | 22.84万 USD |
| 销货成本 | 2438.23万 USD | 2420.45万 USD | 1575.36万 USD | 264.9万 USD | 11.78万 USD |
| 毛利 | 1192.36万 USD | 1066.98万 USD | 833.92万 USD | 169.66万 USD | 11.06万 USD |
| 研究与开发 | 60.43万 USD | 93.39万 USD | 185.58万 USD | 81.19万 USD | 67.22万 USD |
| 销售、一般及管理费用 | 1962.66万 USD | 1493.75万 USD | 1082.98万 USD | 947.84万 USD | 186.58万 USD |
| 营业费用 | 1640.24万 USD | 1648.19万 USD | 1312.45万 USD | 1037.06万 USD | 255.07万 USD |
| 利息收入 | 28.09万 USD | 49.6万 USD | 81.2万 USD | 51.87万 USD | — |
| 利息支出 | — | 8774 USD | 13.73万 USD | 3.94万 USD | 32.88万 USD |
| 折旧和摊销 | 33.21万 USD | 22.35万 USD | 14.91万 USD | 2.52万 USD | 1.27万 USD |
| 营业利润 | −447.88万 USD | −581.21万 USD | −478.53万 USD | −867.4万 USD | −244.01万 USD |
| 净利润 | −597.54万 USD | −513.41万 USD | −450.6万 USD | −2674.44万 USD | −1243.64万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年6月1日 | 1:10 | — | — |
股票拆分 | 2024年8月8日 | 1:20 | — | — |
股票拆分 | 2024年4月17日 | 1:100 | — | — |
股票拆分 | 2022年2月9日 | 1:200 | — | — |
股票拆分 | 2020年4月6日 | 1:20 | — | — |
股票拆分 | 2019年2月1日 | 1:20 | — | — |
已生效 2026年6月1日
1:10
已生效 2024年8月8日
1:20
已生效 2024年4月17日
1:100
已生效 2022年2月9日
1:200
已生效 2020年4月6日
1:20
已生效 2019年2月1日
1:20
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
